Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Genmab, Seattle Genetics Expand ADC Pact | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Genmab, Seattle Genetics Expand ADC Pact

Genmab and Seattle Genetics have entered into their second antibody-drug conjugate (ADC) research collaboration under which Genmab has rights to use Seattle Genetics’ ADC technology with HuMax-CD74.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Genmab and Seattle Genetics have entered into their second antibody-drug conjugate (ADC) research collaboration under which Genmab has rights to use Seattle Genetics’ ADC technology with HuMax-CD74, an antibody in preclinical development to treat a range of hematological malignancies and solid tumors. Seattle Genetics received an undisclosed upfront payment and has the right to exercise a co-development and co-commercialization option for any resulting products at the end of Phase I development.

Genmab is responsible for research, manufacturing, preclinical development and Phase I evaluation. Seattle Genetics will receive research support payments. If Seattle Genetics selects a product at the end of Phase I, Genmab will receive a payment and the companies would co-develop and share all future costs and profits equally. If Seattle Genetics does not opt in to an ADC product, Genmab would pay Seattle Genetics fees, milestones and royalties on sales.

“The expanded collaboration with Genmab provides us with another opportunity to augment our future ADC product pipeline based on data from a phase I clinical trial,” said Eric L. Dobmeier, Chief Business Officer of Seattle Genetics. “We now have co-development options for four of our collaborators’ ADC programs, reflecting our ability to maximize the potential of our technology through strategic collaborations with organizations that have complementary capabilities.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters